Home > Neurology > MS Virtual 2020 > Treatment Strategies and Results > Management of progressive MS with approved DMT

Management of progressive MS with approved DMT

Presented By
Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain
Conference
MS Virtual 2020
Trial
ASCEND, MS-SMART
In an invited lecture, Prof. Xavier Montalban (Vall d'Hebron University Hospital, Spain) discussed the management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment (DMT) highlighting their limitations and reasons they have failed [1]. For PPMS in particular, current treatment options are limited to ocrelizumab, but the ongoing trials were discussed. Drugs considered for active SPMS in the 2018 ECTRIMS/EAN MS treatment guidelines are interferon-1a or -1b, taking into account the dubious efficacy as well as the safety and tolerability profile [2]. Other options mentioned for active SPMS are mitoxantrone, ocrelizumab, or cladribine. Possible additions to this list are siponimod and ozanimod, which were recently approved for relapsing MS, and ofatumumab, which was approved for active SPMS (among others) by the FDA in August 2020. For PPMS, only 1 DMT has been approved specifically, which is ocrelizumab. Pr...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on